Unknown PHASE2 INTERVENTIONAL 4-arm NCT04739917

Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers

Safety and Protective Efficacy of a Synthetic Vaccine Derived From the CS Protein of Plasmodium Vivax: a Double-blind, Placebo-controlled, Randomized Clinical Trial in naïve and Pre-immune Colombian Volunteers

Sponsor: Malaria Vaccine and Drug Development Center

Conditions Malaria, Vivax

Interventions Placebo SSN Montanide ISA-51 1 mL Vaccine PvCS N+C+R 150 mcg

Updated 6 times since 2021 Last updated: Feb 25, 2021 Started: Jun 1, 2021 Primary completion: Jun 1, 2022 Completion: Dec 1, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Malaria, Vivax, this trial is ongoing. The trial is conducted by Malaria Vaccine and Drug Development Center and has accumulated 6 data snapshots since 2021. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Nov 2025 — Present [monthly]

Unknown PHASE2
Sep 2025 — Nov 2025 [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Mar 2021 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Malaria Vaccine and Drug Development Center

Data source: Malaria Vaccine and Drug Development Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cali, Colombia